Paper of the Month

ESO Paper of the Month

This iniative is brought to you  by the council of fellows to highlight interesting and relevant papers published by ESO members or with special relevance to Europe. Papers will be suggested by members of the Paper of the Month Group (see below for more details). ESO members can also nominate a paper by sending it directly to info@ESO-stroke.org

March 2020

Paper: Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation

This is an  individual patient data pooled analysis of 5314 patients, which addresses the question whether patients who have an ischemic stroke while anticoagulated should be changed to a different anticoagulant or not.  It is a clinically relevant topic and will help in decision making, but still many questions remain unanswered. 

Seiffge DJ, De Marchis GM, Koga M, Paciaroni M, Wilson D, Cappellari M, et al. Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation. Ann Neurol 2020 Feb 12.

 https://onlinelibrary.wiley.com/doi/10.1002/ana.25700

Access Full Paper

February 2020

Paper: Safety and efficacy of dual antiplatelet pretreatment in ischemic stroke patients treated with IV thrombolysis: A systematic review and meta-analysis. 

In this paper, the authors report safety and efficacy of iv alteplase in ischemic stroke patients who were on dual antiplatelets. Antiplatelet pre-treatment is not an exclusion criterion for the use of iv alteplase; however, some concern persists particularly because of conflicting data and recent suggestions from ENCHANTED trial that prior antiplatelets use is associated with increased symptomatic intracerebral haemorrhage risk. This is therefore an important study which tackles an important clinically relevant question. Also, this is a robust meta analysis of almost 70 000 patients. In unadjusted analyses, they noted increased risk of symptomatic intracerebral haemorrhages amongst patients on dual anti platelets who received iv alteplase for acute ischemic stroke; this, however, was not associated with poor functional outcomes. In a adjusted analysis however, prior treatment with dual anti platelets was not associated with increased risk of symptomatic intracerebral haemorrhages. This meta analysis adds to our evidence in favour of the use of iv alteplase in ischemic stroke patients who are on dual anti platelets.

Malhotra K, Katsanos AH, Goyal N, Ahmed N, Strbian D, Palaiodimou L, Karapanayiotides T, Alexandrov AW, Grotta JC, Alexandrov AV, Tsivgoulis G. Safety and efficacy of dual antiplatelet pretreatment in ischemic stroke patients treated with IV thrombolysis: A systematic review and meta-analysis. Neurology. 2020 Jan 20. pii: 10.1212/WNL.0000000000008961. doi: 10.1212/WNL.0000000000008961.

Access Full Paper

January 2020

Paper: Age and Sex Differences in Ischemic Stroke Treatment in a Nationwide Analysis of 1.11 Million Hospitalized Cases

An interesting and methodologically balanced nationwide registry study examining changes of access to stroke units and recanalization therapies (both IVT and MT) over time, age and sex differences. Read this and contemplate why men are more likely to be admitted to a stroke unit, but women are more likely to be treated by mechanical thrombectomy.

Weber R, Krogias C, Eyding J, Bartig D, Meves SH, Katsanos AH, Caso V, Hacke W. Age and Sex Differences in Ischemic Stroke Treatment in a Nationwide Analysis of 1.11 Million Hospitalized Cases. Stroke 2019 Dec;50(12):3494-3502. https://www.ahajournals.org/doi/10.1161/STROKEAHA.119.026723

December 2019

Paper: Outcomes of patients with stroke treated with thrombolysis according to prestroke Rankin Scale scores

“Was the patient independent before this stroke?” The answer to this question is no longer needed to decide whether to give thrombolysis or not t a patient with ischaemic stroke presenting within 4.5 h from the event. Even patients with significant disability (mRS up to 4) may improve and return to their previous level if appropriately treated, according to this paper by Gumbinger et al, published recently in Neurology. The Authors found that intravenous thrombolysis in patients with pre-stroke mRS (pRS) scores of 0 to 4 was associated with a higher chance of returning to their baseline (or a modified Rankin Scale score of 0/1). Only patients with a pre-stroke Rankin of 5 did not benefit from thrombolysis. So another barrier to treatment is disappearing…

Gumbinger C, Ringleb P, Ippen F, Ungerer M, Reuter B, Bruder I, Daffertshofer M, Stock C; Stroke Working Group of Baden-Württemberg. Outcomes of patients with stroke treated with thrombolysis according to prestroke Rankin Scale scores. Neurology. 2019 Nov 12;93(20):e1834-e1843. doi: 10.1212/WNL.0000000000008468.

November 2019

Paper: Anticoagulation after stroke in patients with atrial fibrillation: to bridge or not with low-molecular-weight heparin?

This month’s paper is of particular interest as it addresses an area of clinical uncertainty which affects daily practice. Should we bridge with full dose heparin/low molecular weight heparin when faced with a patient in AF who has had a minor stroke? Altavilla et al’s large observational study suggests ‘no’. Both ischemic and haemorrhagic strokes were more frequent in the bridged group. However, the study is not randomized, and neither multivariate analysis nor propensity matching can fully exclude biases. However, while we are waiting for results of on-going clinical trials such as ELAN, these results should make us stop and think when considering bridging.

 

Altavilla R, Caso V, Bandini F, Agnelli G, Tsivgoulis G, Yaghi S, et al.. Anticoagulation after stroke in patients with atrial fibrillation: to bridge or not with low-molecular-weight heparin? Stroke. 2019; 50:2093–2100.

doi: 10.1161/STROKEAHA.118.022856. PMID:31221054

Selection Process

Paper Selection Process

The paper should be based on stroke research with a substantial European input especially from ESO-members, and no specific journals are preferred. Focus will be on including all topics within the field of stroke including acute, prevention, rehabilitation, and life after stroke. If the paper is not published in English, the nomination must include a translation to qualify.

There are two methods to identify a “paper of the month”:

  1. Nominations of paper (not own paper)
  2. Search for papers by the task force

Nominations of papers will be accepted until 10th of the following month and relate to the calendar date of the month before (e.g. the paper of the month in February will relate to January publications).

Process of publication of the paper of the month on the ESO Website

The paper of the month will be published here on 20th of the month following the publication date.

Publication on the website will provide a link to the full paper, where freely available without infringing copyright, or to the abstract on Pubmed.

Members of the Council of Fellows Paper of the Month Task Force

The Task Force is comprised of FESO. Current members are:

Diana Aguiar de Sousa, Anita Arsovska, Hugues Chabriat, Hanne Christensen, Ana Fonseca, Nishant Mishra, Vladimir Nosal, Stefano Ricci, Christine Roffe, Augusto Zaninelli, Marialuisa Zedde

Administrative contact

Luzia Balmer | ESO ‎Head Office